Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Merck Foundation has pioneered a new era in fertility care across Africa and Asia by training local embryologists and ...

Merck Foundation Together with African and Asian First Ladies Mark 'World Assisted Reproductive Technology Day' 2025 ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Investors might want to bet on Merck KGaA (MKKGY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates - ...

Merck KGaA is the world's largest still-operating pharma and healthcare company, with a 300+ year history. It has absolutely stellar fundamentals, and what risks do exist are well-covered by the ...

Aside from ongoing debt servicing requirements, Merck KGaA has few demands on its free cash flow (EUR 3 billion in 2022) other than its common stock dividend (EUR 0.2 billion in 2022) and ongoing ...

In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally.

FRANKFURT, March 7 (Reuters) - Merck KGaA (MRCG.DE) forecast a return to modest operating earnings growth this year but only when adjusted for currency headwinds, citing a gradual recovery in ...

Merck KGaA’s top-selling product in 2024 was Erbitux (cetuximab), which generated €1.16bn ($1.25bn) in revenue. The drug – a monoclonal antibody used in the treatment of certain head and ...

Merck KGaA’s forecast caveat came as the company tallied 5.2 billion euros ($5.41 billion) in first-quarter revenue, signaling a 12.2% increase over the same period in 2021.

Germany’s Merck KGaA said Thursday that it expects a challenging 2023, with adjusted earnings forecast to be stable or decline slightly and a hit from foreign-exchange rates, as it reported a ...